Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27917812 | 0.84 | HTR2A (0.58) | SPRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL4539607 | 0.83 | SPR (0.46) | SPRHTR2AHTR2CALDH1A1AKR1C3 | |
| SCHEMBL2928335 | 0.82 | ELOVL6 (0.45) | SPRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL21626630 | 0.82 | GPR119 (0.60) | MEN1KMT2AEPHX2 | |
| SCHEMBL17410625 | 0.82 | KMT2A (0.49) | HTR2AHTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL1498303 | 0.80 | CNR1 (0.51) | — | |
| SCHEMBL1809004 | 0.80 | KAT6A (0.44) | SPRHTR2AKMT2AALDH1A1DRD2 | |
| SCHEMBL6095946 | 0.79 | DRD2 (0.47) | HTR2AHTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL8546806 | 0.78 | AKR1C3 (0.51) | SPRMEN1KMT2AALDH1A1AKR1C3 | |
| SCHEMBL1808102 | 0.77 | CACNA1B (0.48) | SPRHTR2AHTR2CEPHX2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | SPR 1246/4885HTR2A 3563/4885HTR2C 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.